167 related articles for article (PubMed ID: 33956412)
1. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
[No Abstract] [Full Text] [Related]
2. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
Steele JM; Seabury RW; Hale CM; Mogle BT
J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
[TBL] [Abstract][Full Text] [Related]
3. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
[TBL] [Abstract][Full Text] [Related]
5. [Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon].
Zahornacký O; Novotný M
Klin Mikrobiol Infekc Lek; 2020 Jun; 26(2):51-53. PubMed ID: 33389741
[TBL] [Abstract][Full Text] [Related]
6. French national cohort of first use of dalbavancin: A high proportion of off-label use.
Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
[TBL] [Abstract][Full Text] [Related]
7. New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
Kollef MH
Crit Care Resusc; 2009 Dec; 11(4):282-6. PubMed ID: 20001879
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Esposito S; Noviello S; Leone S
Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.
Barnea Y; Lerner A; Aizic A; Navon-Venezia S; Rachi E; Dunne MW; Puttagunta S; Carmeli Y
J Antimicrob Chemother; 2016 Feb; 71(2):460-3. PubMed ID: 26518048
[TBL] [Abstract][Full Text] [Related]
11.
Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
[No Abstract] [Full Text] [Related]
12. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
[TBL] [Abstract][Full Text] [Related]
13. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.
Guzek A; Suwalski G; Tomaszewski D; Rybicki Z
J Cardiothorac Surg; 2018 Jan; 13(1):3. PubMed ID: 29304832
[TBL] [Abstract][Full Text] [Related]
16. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
McCurdy SP; Jones RN; Mendes RE; Puttagunta S; Dunne MW
Antimicrob Agents Chemother; 2015 Aug; 59(8):5007-9. PubMed ID: 25987636
[TBL] [Abstract][Full Text] [Related]
18. [Prolonged treatment with dalbavancin in prosthetic hip infection by methicillin-resistant Staphylococcus epidermidis].
Trujillano Ruiz A; Mesquida Riera J; Serrano Fabiá MA; Riera Pérez E; Mejía Benard A; Taberner Ferrer MD
Rev Esp Quimioter; 2019 Apr; 32(2):203-204. PubMed ID: 30868837
[No Abstract] [Full Text] [Related]
19. Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report.
Álvarez Otero J; Sanjurjo Rivo A; Lamas Ferreiro JL; de la Fuente Aguado J
Rev Esp Quimioter; 2019 Jun; 32(3):276-277. PubMed ID: 31037932
[No Abstract] [Full Text] [Related]
20. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
